SZSE Ticker: 300404

Guangzhou Boji Medical & Biotechnological Co., Ltd.

广州博济医药生物技术股份有限公司

博济医药

BOJI CRO

Listing Date: 2015-04-24

Board: GEM

Industry Classification: Research & Development

[Exploration of the outlet · CXO] The high-speed growth of construction in progress after deducting non-profits in the first quarter helped AH shares "stand up"

Post date May 11, 2022 — 12:25 Post Lock

Boji Pharmaceutical (300404): Record Form of 2021 Annual Results Briefing Meeting on May 6, 2022 CFi.CN Zhongcai Network

Post date May 7, 2022 — 19:41 Post Lock

Boji Pharmaceutical (300404): Record Form of 2021 Annual Results Briefing Meeting on May 6, 2022 CFi.CN Zhongcai Network

Post date May 7, 2022 — 19:41 Post Lock

Boji Pharmaceutical has been surveyed by 18 institutions: the company has always had a layout and development in the field of traditional Chinese medicine research and development, and traditional Chinese medicine has always been the company's characteristic field (with survey questions and answers)

Post date April 28, 2022 — 21:21 Post Lock

Many countries have unexplained hepatitis, and the board secretaries of many pharmaceutical companies have responded to hepatitis treatment-related products – yqqlm

Post date April 26, 2022 — 19:51 Post Lock

Hepatitis concept stocks strengthened in the afternoon as acute hepatitis cases in children of unknown cause spread again_Stock News_Market Gold Online

Post date April 26, 2022 — 15:20 Post Lock

Boji Medicine (300404): Legal Opinion of Beijing Kangda (Guangzhou) Law Firm on the Legal Opinion of the Company's 2020 Stock Option Incentive Plan to Cancel Partial Stock Options- CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:10 Post Lock

Boji Medicine (300404): Expiration of the term of independent directors and by-election of independent directors- CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:10 Post Lock

Boji Pharmaceutical (300404): Independent Director's Independent Opinion on the 20th Meeting of the Fourth Board of Directors and Related Matters in 2021- CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:10 Post Lock

Boji Pharmaceutical (300404): Notice of Convening the 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:10 Post Lock

[First Quarterly Report] Boji Pharmaceutical (300404): 2022 First Quarterly Report Disclosure Announcement CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:09 Post Lock

Boji Pharmaceutical (300404): 2021 Independent Director Debriefing Report (Liu Guochang) CFi.CN

Post date April 26, 2022 — 15:08 Post Lock

Boji Pharmaceutical (300404): The company's 2021 profit distribution plan CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:07 Post Lock

Boji Pharmaceutical (300404): Provision for asset impairment and write-off of assets in 2021 CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:06 Post Lock

Boji Pharmaceutical (300404): Cancellation of some stock options- CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:06 Post Lock

Boji Pharma (300404): Special Verification Opinions of CITIC Securities Co., Ltd. on the Extension of Part of the Investment Projects of Boji Pharma Technology Co., Ltd. CFi.CN Zhongcai.com

Post date April 26, 2022 — 15:05 Post Lock

Boji Pharmaceutical (300404): 2021 Independent Director Debriefing Report (Hao Yingqi) CFi.CN

Post date April 26, 2022 — 15:04 Post Lock

Boji Pharmaceutical (300404): Statement of Nominee for Independent Director- CFi.CN Zhongcai Network

Post date April 26, 2022 — 15:03 Post Lock

Boji Pharma (300404): CITIC Securities Co., Ltd.'s special inspection opinion on the deposit and use of funds raised by Boji Pharma Technology Co., Ltd. in 2021- CFi.CN Zhongcai.com

Post date April 26, 2022 — 15:02 Post Lock

Boji Pharmaceutical (300404): 2021 Independent Director Debriefing Report (Yu Pengyi) CFi.CN

Post date April 26, 2022 — 15:01 Post Lock

Want to see more data? Registered subscribers can see all the data.